This study provides strong rationale for the continued clinical investigation and design of clinical trials with rational combinations of targeted therapies including HDAC and mTOR blockade for the treatment of patients with advanced and castrate resistant PCa. The gene discussed is HDAC9; the disease is posterior cortical atrophy.